Preferences for Injectable PrEP Among Young U.S. Cisgender Men and Transgender Women and Men Who Have Sex with Men
- PMID: 28929260
- DOI: 10.1007/s10508-017-1049-7
Preferences for Injectable PrEP Among Young U.S. Cisgender Men and Transgender Women and Men Who Have Sex with Men
Abstract
Young men who have sex with men account for approximately 20% of incident HIV infections in the U.S. Antiretroviral pre-exposure prophylaxis (PrEP) administered as a daily pill has been shown to decrease HIV acquisition in at-risk individuals. New modalities for PrEP are being developed and tested, including injectable PrEP; however, acceptability of these emerging modalities has not yet been examined in youth. We conducted six focus groups with 36 young men and transgender men and women who have sex with men in Boston, Chicago, and Los Angeles in 2016 to assess interest in and preference for different PrEP modalities. Youth were purposively recruited based on diversity of age, race/ethnicity, and prior PrEP experience. Data were coded using content coding based on key domains of the interview guide, in particular around the central themes of interest in and barriers and facilitators to injectable PrEP use. Participants were knowledgeable about oral PrEP but suggested barriers to broader uptake, including stigma, marginalization, and access to information. While participants were split on preference for injectable versus oral PrEP, they agreed quarterly injections may be more manageable and better for those who have adherence difficulties and for those who engage in sex more frequently. Concerns specific to injectable PrEP included: severity/duration of side effects, pain, level of protection prior to next injection, distrust of medical system and injections, and cost. Understanding barriers to and preferences for diverse prevention modalities will allow for more HIV prevention options, improved products, and better interventions, thus allowing individuals to make informed HIV prevention choices.
Keywords: HIV prevention; Men who have sex with men; Pre-exposure prophylaxis; Sexual orientation; Transgender.
Similar articles
-
HPTN 083-02: factors influencing adherence to injectable PrEP and retention in an injectable PrEP study.J Int AIDS Soc. 2024 May;27(5):e26252. doi: 10.1002/jia2.26252. J Int AIDS Soc. 2024. PMID: 38783534 Free PMC article.
-
High interest in a long-acting injectable formulation of pre-exposure prophylaxis for HIV in young men who have sex with men in NYC: a P18 cohort substudy.PLoS One. 2014 Dec 11;9(12):e114700. doi: 10.1371/journal.pone.0114700. eCollection 2014. PLoS One. 2014. PMID: 25502768 Free PMC article.
-
Geographic and Individual Associations with PrEP Stigma: Results from the RADAR Cohort of Diverse Young Men Who have Sex with Men and Transgender Women.AIDS Behav. 2018 Sep;22(9):3044-3056. doi: 10.1007/s10461-018-2159-5. AIDS Behav. 2018. PMID: 29789985 Free PMC article.
-
HIV pre-exposure prophylaxis (PrEP) awareness and acceptability among trans women: a review.AIDS Care. 2019 Oct;31(10):1234-1240. doi: 10.1080/09540121.2019.1612014. Epub 2019 May 1. AIDS Care. 2019. PMID: 31043069 Review.
-
A Global Estimate of the Acceptability of Pre-exposure Prophylaxis for HIV Among Men Who have Sex with Men: A Systematic Review and Meta-analysis.AIDS Behav. 2018 Apr;22(4):1063-1074. doi: 10.1007/s10461-017-1675-z. AIDS Behav. 2018. PMID: 28176168
Cited by
-
Barriers and facilitators to pre-exposure prophylaxis uptake among Black/African American men who have sex with other men in Iowa: COM-B model analysis.Ther Adv Infect Dis. 2024 Jul 26;11:20499361241267151. doi: 10.1177/20499361241267151. eCollection 2024 Jan-Dec. Ther Adv Infect Dis. 2024. PMID: 39070701 Free PMC article.
-
A missing perspective: injectable pre-exposure prophylaxis for people who inject drugs.AIDS Care. 2019 Oct;31(10):1214-1220. doi: 10.1080/09540121.2019.1587356. Epub 2019 Mar 1. AIDS Care. 2019. PMID: 30822103 Free PMC article.
-
Pre-exposure prophylaxis for HIV prevention preferences among young adult African American men who have sex with men.PLoS One. 2018 Dec 28;13(12):e0209484. doi: 10.1371/journal.pone.0209484. eCollection 2018. PLoS One. 2018. PMID: 30592756 Free PMC article.
-
Engagement in Care, Awareness, and Interest in Long-Acting Injectable Anti-Retroviral Therapy.AIDS Behav. 2024 Oct;28(10):3315-3325. doi: 10.1007/s10461-024-04423-x. Epub 2024 Jul 1. AIDS Behav. 2024. PMID: 38954172 Free PMC article.
-
Two-dose emtricitabine/tenofovir alafenamide plus bictegravir prophylaxis protects macaques against SHIV infection.J Antimicrob Chemother. 2021 Feb 11;76(3):692-698. doi: 10.1093/jac/dkaa476. J Antimicrob Chemother. 2021. PMID: 33202006 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous